HomeALCLS • EPA
add
Cellectis SA
Nakaraang pagsara
€2.79
Sakop ng araw
€2.61 - €2.81
Sakop ng taon
€1.01 - €3.20
Market cap
202.41M EUR
Average na Volume
331.55K
P/E ratio
-
Dividend yield
-
Primary exchange
EPA
Mga balita tungkol sa merkado
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Hun 2025info | Y/Y na pagbabago |
|---|---|---|
Kita | 18.19M | 91.44% |
Gastos sa pagpapatakbo | 27.78M | 3.99% |
Net na kita | -23.74M | 6.07% |
Net profit margin | -130.46 | 50.93% |
Kita sa bawat share | -0.22 | 18.52% |
EBITDA | -6.46M | 55.36% |
Aktuwal na % ng binabayarang buwis | — | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Hun 2025info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 59.81M | -59.87% |
Kabuuang asset | 353.97M | -13.06% |
Kabuuang sagutin | 256.86M | -0.65% |
Kabuuang equity | 97.11M | — |
Natitirang share | 72.33M | — |
Presyo para makapag-book | 2.08 | — |
Return on assets | -6.67% | — |
Return on capital | -11.97% | — |
Cash Flow
Net change in cash
| (USD) | Hun 2025info | Y/Y na pagbabago |
|---|---|---|
Net na kita | -23.74M | 6.07% |
Cash mula sa mga operasyon | -10.31M | -119.76% |
Cash mula sa pag-invest | -52.72M | 50.47% |
Cash mula sa financing | -4.27M | -105.44% |
Net change in cash | -67.83M | -360.16% |
Malayang cash flow | -23.11M | 16.32% |
Tungkol
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina. Wikipedia
Itinatag
1999
Website
Mga Empleyado
219
